Los Angeles Capital Management LLC Syros Pharmaceuticals, Inc. Transaction History

Los Angeles Capital Management LLC

  • $24.7 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 05, 2022
SELL
$0.69 - $1.21 $172,136 - $301,862
-249,473 Closed
0 $0
Q1 2022

May 06, 2022
SELL
$1.02 - $3.8 $8,381 - $31,224
-8,217 Reduced 3.19%
249,473 $297,000
Q4 2021

Feb 03, 2022
SELL
$3.26 - $4.66 $4,068 - $5,815
-1,248 Reduced 0.48%
257,690 $840,000
Q3 2021

Nov 08, 2021
SELL
$4.08 - $5.66 $51,285 - $71,146
-12,570 Reduced 4.63%
258,938 $1.16 Million
Q2 2021

Aug 05, 2021
BUY
$5.01 - $7.48 $907,446 - $1.35 Million
181,127 Added 200.4%
271,508 $1.48 Million
Q1 2021

May 05, 2021
SELL
$7.19 - $14.95 $179,354 - $372,927
-24,945 Reduced 21.63%
90,381 $676,000
Q4 2020

Feb 04, 2021
BUY
$6.66 - $14.66 $59,973 - $132,013
9,005 Added 8.47%
115,326 $1.25 Million
Q3 2020

Nov 02, 2020
BUY
$8.69 - $14.47 $201,686 - $335,834
23,209 Added 27.92%
106,321 $940,000
Q2 2020

Aug 05, 2020
BUY
$5.21 - $11.03 $188,966 - $400,058
36,270 Added 77.43%
83,112 $885,000
Q1 2020

May 04, 2020
BUY
$4.46 - $9.2 $158,958 - $327,897
35,641 Added 318.19%
46,842 $278,000
Q4 2019

Feb 07, 2020
BUY
$4.52 - $10.1 $50,628 - $113,130
11,201 New
11,201 $77,000
Q3 2019

Nov 07, 2019
SELL
$7.14 - $11.65 $288,241 - $470,310
-40,370 Closed
0 $0
Q2 2019

Jul 29, 2019
SELL
$5.5 - $9.75 $55 - $97
-10 Reduced 0.02%
40,370 $374,000
Q1 2019

Apr 25, 2019
BUY
$5.51 - $9.59 $17,081 - $29,729
3,100 Added 8.32%
40,380 $369,000
Q4 2018

Feb 11, 2019
SELL
$5.55 - $11.34 $1,942 - $3,969
-350 Reduced 0.93%
37,280 $208,000
Q3 2018

Nov 05, 2018
SELL
$9.74 - $12.92 $216,812 - $287,599
-22,260 Reduced 37.17%
37,630 $448,000
Q2 2018

Jul 31, 2018
BUY
$10.16 - $13.65 $608,482 - $817,498
59,890 New
59,890 $611,000

About Syros Pharmaceuticals, Inc.

SYRS Quotes by TradingView
  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $4.25M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email